MedCo Technology

About MedCo Technology

MedCo Technology, known in China as 麦得科科技有限公司, is a developer of ophthalmic medical devices, established on December 27, 2016. The company was founded by individuals with extensive experience in the ophthalmic medical field and is legally represented by Liu Liang. Its technical team is composed of scientists from established international ophthalmic device companies. Headquartered in Hangzhou, China, MedCo Technology has established a product development and marketing center, complemented by a research, production, and sales base in the United States.

The company focuses on providing full-cycle solutions for the ophthalmic medical sector, targeting eye diseases such as cataracts, high myopia, and dry eye. Its business model revolves around the development, manufacturing, and sale of these specialized medical devices to ophthalmologists and other eye care professionals globally. A significant milestone was achieved in September 2024, when the company secured nearly 200 million RMB in a Series B financing round, with funds intended to advance product pipeline registration and market expansion. Investors include Heda Ventures, Sunland Fund, China Merchants Capital, and Decheng Capital China Management.

MedCo Technology's product portfolio is built upon its proprietary technological platform, which includes novel polymer material synthesis, high-precision processing, and advanced optical design. Key products include the MPL refractive lens for myopia, intraocular lenses (IOL) for cataracts, and defocus glasses for myopia control. One of its notable products is a smart photochromic intraocular lens. The company's proprietary soft refractive lens material has undergone 20 years of clinical validation, demonstrating biocompatibility and stability. These products are positioned to address gaps in the domestic Chinese market for mid-to-high-end ophthalmic devices and are also being introduced to international markets, such as Southeast Asia.